Personalized management of functional gastrointestinal disorders in Anhui, China

Submission date	Recruitment status	[X] Prospectively registered
17/06/2021	Recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
12/07/2021	Ongoing	☐ Results
Last Edited	Condition category	Individual participant data
12/10/2021	Digestive System	Record updated in last year

Plain English summary of protocol

Background and study aims

Functional gastrointestinal disorders (FGIDs) can affect any part of the gastrointestinal (GI) tract, including the food pipe, stomach and intestines. They are disorders of function (how the GI tract works). Quality of life impairment and economic loss (both direct and indirect) because of FGIDs are huge. FGIDs have a long course and repeated symptoms, and so cause serious and enduring physical, psychological as well as sociological suffering. Personalized management of FGIDs (PM-FGIDs) aims to prevent and reduce the risk and harms of FGIDs through six behaviors, including:

- 1. Attending and responding to project communications
- 2. Changing unhealthy diet habits or practices
- 3. Reducing tobacco and alcohol consumption
- 4. Coping with psychological and sleep problems
- 5. Maintaining adequate physical exercise/activities
- 6. Using clinical examination and treatment

This study aims to test the effectiveness of PM-FGIDs and to identify key facilitators, barriers and corresponding strategies for the spread and implementation of PM-FGIDs.

Who can participate?

Patients aged 18-70 years with FGIDs at 26 general hospitals of Anhui province, China

What does the study involve?

Participants will either receive care-as-usual (CAU) or CAU plus PM-FGIDs over the study period. Participants' scores of overall treatment effect and data about their use of healthcare services, changes in the six behaviors, and quality of life will be measured using questionnaires at the start of the study and every 6 months for the following 5 years.

What are the possible benefits and risks of participating?

There are not thought to be any risks involved with participating in the study. A possible benefit could be that PM-FGIDs prevent and reduce the risk and harms of FGIDs.

Where is the study run from?

Anhui Provincial Center for Disease Control and Prevention (China)

When is the study starting and how long is it expected to run for? November 2020 to October 2026

Who is funding the study? Anhui Provincial Center for Disease Control and Prevention (China)

Who is the main contact? Miss Mengsha Tang mengshatang@sina.com

Contact information

Type(s)

Public

Contact name

Miss Mengsha Tang

ORCID ID

https://orcid.org/0000-0002-7108-5000

Contact details

Anhui Medical University 81 Meishan Road Hefei China 230032 +86 (0)551 65116395 mengshatang@sina.com

Type(s)

Scientific

Contact name

Miss Mengsha Tang

ORCID ID

https://orcid.org/0000-0002-7108-5000

Contact details

Anhui Medical University 81 Meishan Road Hefei China 230032 +86 (0)551 65116395 mengshatang@sina.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

Personalized management of functional gastrointestinal disorders based on serial assessment and telemedicine in Anhui, China: a randomized controlled trial

Acronym

PM-FGIDs

Study objectives

- 1. Compared to those in the control condition, patients in the personalized management of functional gastrointestinal disorders (PM-FGIDs) intervention will demonstrate: higher scores on the overall treatment effect (OTE) of gastrointestinal symptoms and objective behaviors including project communications, healthy diet, physical activities, tobacco/alcohol consumption, psychological/sleep problems coping, and clinical examination/treatment.
- 2. Key facilitators, barriers and corresponding strategies for the spread and implementation of PM-FGIDs will be identified.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 16/07/2021, Anhui Medical University Biomedical Ethics Committee (Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China; +86 0551-65161053; renzhenhua@ahmu.edu. cn), ref: 20210648.

Study design

Cluster randomized controlled trial

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Study setting(s)

Hospital

Study type(s)

Quality of life

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Functional gastrointestinal disorders

Interventions

This study adopts a cluster randomized controlled trial design involving 26 general hospitals in Anhui province, China. These hospitals are randomly assigned by a professional statistician outside the project team into equal intervention and control arms. The control group receives care-as-usual (CAU) while the intervention group receives CAU plus personalized management of functional gastrointestinal disorders (PM-FGIDs). Project evaluation applies to both the intervention and control groups using the same questionnaire and at the same time points, i.e., baseline and every 6 months after baseline. The trial design and implementation are overseen by a steering committee. Analysis and reporting of the trial strictly follows the CONSORT guidelines.

PM-FGIDs aims to prevent and reduce the risk and harms of FGIDs through six objective behaviors, including:

- 1. Attending and responding to project communications
- 2. Changing unhealthy diet habits or practices
- 3. Reducing tobacco and alcohol consumption
- 4. Coping with psychological and sleep problems
- 5. Maintaining adequate physical exercise/activities
- 6. Using clinical examination and treatment

The above objective behaviors are promoted through four interventions venues: supervised machine communication, daily education or reminder messages, quarterly signed feedback, and personal web account and pages. The design of these measures is guided by proven theories or strategies including system synergy, health belief model, social cognition theory, motivational interviewing, and computerized tailoring. Detailed intervention varies from patient to patient due to the personalized nature of the intervention.

Intervention Type

Behavioural

Primary outcome measure

The overall treatment effect (OTE) of gastrointestinal symptoms measured using a 7-point Likert scale (the question is "How have your gastrointestinal symptoms changed after treatment?", and the answers include "much better", "improvement", "slight improvement", "no change", "slight deterioration", "worse", and "deteriorated") at baseline and every 3 months after baseline for 5 years

Secondary outcome measures

Measured using structured questionnaires at baseline and every 6 months after baseline for 5 years:

- 1. Quality of life measured using EQ5D-5L
- 2. Participant's utilization of health services measured using a self-designed patient assessment

questionnaire

3. Changes in the six objective behaviors measured using a self-designed patient assessment questionnaire

Overall study start date

01/11/2020

Completion date

31/10/2026

Eligibility

Key inclusion criteria

- 1. Male and female patients
- 2. 18-70 years old
- 3. Diagnosed with FGIDs according to Rome IV diagnostic criteria
- 4. Able and willing, after informed consent, to participate

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

70 Years

Sex

Both

Target number of participants

2600

Key exclusion criteria

- 1. Serious mental illness, such as schizophrenia or dementia
- 2. History of gastrointestinal surgery, such as gastrectomy or colectomy
- 3. Serious or malignant disease confirmed by a clinician, such as kidney failure or tumor
- 4. Pregnancy or breastfeeding

Date of first enrolment

01/09/2021

Date of final enrolment

30/04/2026

Locations

Countries of recruitment

China

Study participating centre Anhui Provincial Center for Disease Control and Prevention

12560 Fanhua Road Hefei China 230601

Sponsor information

Organisation

Anhui Provincial Center for Disease Control and Prevention

Sponsor details

12560 Fanhua Road Hefei China 230601 +86 (0)551 63674900 ahcdcbgs@ahcdc.com.cn

Sponsor type

Government

Website

http://www.ahcdc.cn/

ROR

https://ror.org/03ddz1316

Funder(s)

Funder type

Government

Funder Name

Anhui Provincial Center for Disease Control and Prevention

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal. No additional documents are available.

Intention to publish date

01/10/2027

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date